The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•15 April 2026•

1 min read

Alaunos Therapeutics Faces Nasdaq Non-Compliance Over Equity Shortfall

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Alaunos Therapeutics received a Nasdaq notice for failing to meet the minimum $2.5 million stockholders’ equity requirement.

Alaunos Therapeutics (TCRT) has received a formal deficiency notice from the Nasdaq Stock Market regarding its failure to meet the minimum stockholders’ equity requirement. The company reported equity of $2.153 million, falling short of the $2.5 million threshold mandated by Nasdaq Listing Rule 5550(b)(1). Consequently, the biotech firm has been granted a 45-day window to submit a comprehensive compliance plan to regain its standing on the exchange. If the plan is accepted, Nasdaq may grant an extension of up to 180 days for the company to demonstrate full compliance. Failure to provide a viable plan or meet the requirements could lead to the delisting of its common stock. Investors are closely monitoring the company's next steps as it seeks to strengthen its balance sheet and maintain its public listing.